A combination of enfortumab vedotin and pembrolizumab has shown promising results in treating patients with advanced bladder cancer, nearly doubling survival rates compared to chemotherapy. Additionally, Johnson & Johnson’s TAR-200 represents a novel treatment prospect, designed to sustain the local release of chemotherapy drug gemcitabine directly into the bladder. Breakthrough nanotechnology in the form of urea-powered nanorobots has also shown great potential, achieving a 90% reduction in bladder tumor size in a mouse model. These advances indicate a promising future for more targeted, effective, and less invasive bladder cancer treatments.
Vietnam’s retail sector faces rising ransomware threats
The lack of cybersecurity protection is hindering the growth of online businesses in Vietnam, according to experts from Viettel Cyber Security (VCS). They addressed challenges